ÎÚÑ»´«Ã½

Cellular Heterogeneity and Relationship to Clinical Outcomes

Cellular therapies are quite heterogeneous by nature, but regulatory and industry groups have focused on defining particular products with "critical product attributes" while minimizing heterogeneity. This session will highlight the potential benefits of cellular heterogeneity, in both immune effector cells and within post-transplant cell populations.

Chair:

°ä°ù²¹¾±²µÌýµþ²â±ð°ù²õ»å´Ç°ù´Ú±ð°ù,Ìý²Ñ¶Ù
University of Pittsburgh
±Ê¾±³Ù³Ù²õ²ú³Ü°ù²µ³ó,Ìý±Ê´¡

Speakers:

´Ü¾±²Ô²¹¾±»å²¹Ìý³Ò´Ç´Ç»å,Ìý±Ê³ó¶Ù
Stanford University School of Medicine
³§³Ù²¹²Ô´Ú´Ç°ù»å,Ìý°ä´¡
Heterogeneity of CD19 CAR T Cells

´³³Ü±ô¾±²¹Ìý°ä²¹°ù²Ô±ð±¹²¹±ô±ð,Ìý²Ñ¶Ù
University of California San Francisco
San Francisco, CA
Purposeful Heterogeneity of CAR T Cells

²Ñ±ð²µ²¹²ÔÌý³¢±ð±¹¾±²Ô²µ²õ
University of British Columbia, Canada
³Õ²¹²Ô³¦´Ç³Ü±¹±ð°ù,Ìýµþ°ä,Ìý°ä´¡±·
Heterogeneity of Cells in Transplantation

Interface of Complement and Coagulation

The complement system and coagulation pathways are the main pillars of immunity and hemostasis respectively that undergo significant activation with injury. While appearing distinct, it is recognized that significant crosstalk exists between the two systems and recently established molecular mechanisms provide insights into a wide variety of disorders. This session will focus on new molecular links identified in complement activation in specific and highly relevant clinical disorders.

Chair:

¶Ù²¹±¹¾±»åÌý°­²¹±¹²¹²Ô²¹²µ³ó,Ìý±Ê³ó¶Ù
New Castle University
Newcastle Upon Tyne, United Kingdom

Speakers:

¶Ù²¹±¹¾±»åÌý°­²¹±¹²¹²Ô²¹²µ³ó,Ìý±Ê³ó¶Ù
New Castle University
Newcastle Upon Tyne, United Kingdom
Complement and the Prothrombotic State

Efthymia Vlachaki, MD, PhD
Hippokrateon Hospital
°Õ³ó±ð²õ²õ²¹±ô´Ç²Ô¾±°ì¾±,Ìý³Ò°ù±ð±ð³¦±ð
Complement Activation and Preclampsia

Lubka T Roumenina, PhD
INSERM UMRS1138 Cordeliers Research Center
±Ê²¹°ù¾±²õ,Ìý¹ó°ù²¹²Ô³¦±ð
Sickle Cell Disease and Complement Activation

Interrogating the Impact of the Intestinal Microbiome on Transplant and Cellular Therapies

Fundamental advances have been achieved in the treatment of patients with hematologic malignancies through transplant and cellular therapy (TCT), including hematopoietic cell transplant and chimeric antigen receptor (CAR) T cell therapy. However, the therapies have limitations, such as relapses and toxicity. TCT outcomes have been associated with the intestinal microbiome. This session will focus on the intestinal microbiome in relation to TCT, from correlative research to interventional studies.

Chair:

²Ñ±ð±ô´Ç»å²âÌý³§³¾¾±³Ù³ó,Ìý²Ñ¶Ù,²Ñ³§
Stanford University School of Medicine
³§³Ù²¹²Ô´Ú´Ç°ù»å,Ìý°ä´¡

Speakers:

Florent Malard, M.D., Ph.D.
Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Service d'Hématologie Clinique et Thérapie Cellulaire,Centre de Recherche Saint-Antoine UMRs938
±Ê²¹°ù¾±²õ,Ìý¹ó°ù²¹²Ô³¦±ð
Fecal Microbiota Transplant As a Strategy to Mitigate Infection and Gvhd Following TCT

Lawrence A David, PhD
Duke University
¶Ù³Ü°ù³ó²¹³¾,Ìý±·°ä
Deciphering Nutritional Intake from Metagenomic Data Using Computational Tools

°Õ±ð²õ²õ²¹Ìý´¡²Ô»å±ð°ù³¾²¹²Ô²Ô,Ìý²Ñ¶Ù,²Ñ±Ê±á
University of North Carolina, Chapel Hill
Chapel Hill, NC
Impact of Antibiotic Exposure on Outcomes Following TCT

Newly Discovered Functions of Megakaryocytes and Platelets

This session will reveal new mechanisms of diseases related to platelet formation and function. Specifically, it will address glycosylation in megakaryocytes (Mks)/platelet functions and diseases; and highlight new insights in thromboinflammation, functions, and diseases of Mks and platelets.

Chair:

´¡±ô±ð²õ²õ²¹²Ô»å°ù²¹Ìýµþ²¹±ô»å³Ü¾±²Ô¾±,Ìý²Ñ¶Ù
Tufts University
²Ñ±ð»å´Ú´Ç°ù»å,Ìý²Ñ´¡

Speakers:

Karin M. Hoffmeister, MD
Versiti Blood Research Institute, Milwaukee, WI
²Ñ¾±±ô·É²¹³Ü°ì±ð±ð,Ìý°Â±õ
Glycans and New Pathogenic Mechanisms of ITP

°Õ´Ç²ú¾±²¹²õÌý±Ê±ð³Ù³ú´Ç±ô»å,Ìý²Ñ¶Ù,²Ñ³§³¦
Charité – Universitätsmedizin Berlin
µþ±ð°ù±ô¾±²Ô,Ìý³Ò±ð°ù³¾²¹²Ô²â
Regulation of Platelet Function During Immobilty

Anna S. Nam, MD
Weill Cornell Medicine
New York, NY
Platelet ER Stress in Thrombosis

Placing the Brakes on Accelerated Aging

Hematologic disorders disproportionately affect older adults; despite this, our understanding of the implications of age on the pathogenesis and treatment of these diseases remains limited. The geroscience field is actively investigating geriomics to aid in distinguishing biological and chronological aging. This session will highlight biological aging assessments for hematologic disease which will be crucial for the identification of targets and development of therapies for this specific population.

Chair:

´¡²õ³ó±ô±ð²âÌý¸é´Ç²õ°ì´Ç,Ìý²Ñ¶Ù
The Ohio State University
°ä´Ç±ô³Ü³¾²ú³Ü²õ,Ìý°¿±á

Speakers:

·¡±ô²õÌý²Ñ²¹²Ô²õ±ð±ô±ô,Ìý±Ê³ó¶Ù
Erasmus Medical Center
¸é´Ç³Ù³Ù±ð°ù»å²¹³¾,Ìý±·±ð³Ù³ó±ð°ù±ô²¹²Ô»å²õ
Ageing of Hematopoietic Stem Cells and Their Niche

Christin E Burd, PhD
Ohio State
°ä´Ç±ô³Ü³¾²ú³Ü²õ,Ìý°¿±á
Geroscience and Geri-Omics in Hematologic Malignancies

Marcel R.M. van den Brink, MD, PhD
City of Hope National Medical Center
¶Ù³Ü²¹°ù³Ù±ð,Ìý°ä´¡
Targeting Rejuvenation Therapies to Decelerate Aging

Special Symposium on the Basic Science of Hemostasis and Thrombosis

This session will highlight emerging topics and the latest discoveries in regulating inflammation at the cross-section of hemostasis, platelets, and vascular biology.

Co-Chairs:

Laurent O. Mosnier, PhD
The Scripps Research Inst.
La Jolla, CA

±á²¹°ù³Ù³¾³Ü³ÙÌý°Â±ð¾±±ô±ð°ù,Ìý±Ê³ó¶Ù
Versiti Blood Research Institute
²Ñ¾±±ô·É²¹³Ü°ì±ð±ð,Ìý°Â±õ

Lijun Xia, MD, PhD
Oklahoma Medical Research Foundation
Oklahoma City, OK

Speakers:

Yesim Dargaud, MD, PhD
Hopital Edouard Herriot Pav. E
³¢²â´Ç²Ô,Ìý¹ó°ù²¹²Ô³¦±ð
Efficacy of Platelet-Inspired Hemostatic Nanoparticles on Bleeding in Von Willebrand Disease Murine Model

´³¾±±ð±ç¾±²Ô²µÌý´Ü³ó³Ü,Ìý±Ê³ó¶Ù
Versiti Blood Research Institute
²Ñ¾±±ô·É²¹³Ü°ì±ð±ð,Ìý°Â±õ
Platelet Integrin Structure, Function and Role in Disease

³Û³ÜÌý±á´Ç³Ü
Qilu Hospital, Cheeloo College of Medicine, Shandong University
´³¾±²Ô²¹²Ô,Ìý°ä±á±·
Platelet TGFb1 in the Pathogenesis of Immune Thrombocytopenia Purpura